Financials CH Biotech R&D Co., Ltd.

Equities

6534

TW0006534001

Agricultural Chemicals

End-of-day quote Taiwan S.E. 06:00:00 2024-07-11 pm EDT 5-day change 1st Jan Change
80.7 TWD -0.37% Intraday chart for CH Biotech R&D Co., Ltd. -4.04% +0.25%

Valuation

Fiscal Period: December 2022 2023 2024
Capitalization 1 7,320 8,275 8,296
Enterprise Value (EV) 1 7,320 8,275 8,296
P/E ratio 16 x - -
Yield - - -
Capitalization / Revenue - 5.46 x 5.08 x
EV / Revenue - 5.46 x 5.08 x
EV / EBITDA - - -
EV / FCF - 14.9 x 24.1 x
FCF Yield - 6.69% 4.15%
Price to Book - - 3.36 x
Nbr of stocks (in thousands) 97,083 102,800 102,800
Reference price 2 75.40 80.50 80.70
Announcement Date 3/21/23 2/29/24 -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024
Net sales 1 - 1,515 1,634
EBITDA - - -
EBIT 1 - 565.9 634
Operating Margin - 37.35% 38.8%
Earnings before Tax (EBT) - - -
Net income 465.4 - -
Net margin - - -
EPS 4.720 - -
Free Cash Flow 1 - 553.6 344
FCF margin - 36.54% 21.05%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 3/21/23 2/29/24 -
1TWD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 824.8 523 120 115
EBITDA - - - -
EBIT 1 496.2 266 -82 -92
Operating Margin 60.16% 50.86% -68.33% -80%
Earnings before Tax (EBT) - - - -
Net income - - - -
Net margin - - - -
EPS - - - -
Dividend per Share - - - -
Announcement Date 5/8/24 - - -
1TWD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024
Net Debt - - -
Net Cash position - - -
Leverage (Debt/EBITDA) - - -
Free Cash Flow 1 - 554 344
ROE (net income / shareholders' equity) - 20.1% 23.7%
ROA (Net income/ Total Assets) - 13.5% 14.8%
Assets - - -
Book Value Per Share 2 - - 24.00
Cash Flow per Share - - -
Capex 1 - 106 180
Capex / Sales - 6.97% 11.02%
Announcement Date 3/21/23 2/29/24 -
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
80.7 TWD
Average target price
89 TWD
Spread / Average Target
+10.29%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 6534 Stock
  4. Financials CH Biotech R&D Co., Ltd.